Please ensure Javascript is enabled for purposes of website accessibility

Why Global Blood Therapeutics Stock Is Sinking Today

By Keith Speights - May 6, 2021 at 10:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing sales for its sickle-cell disease drug.

What happened

Shares of Global Blood Therapeutics (GBT 0.07%) were sinking 8% as of 11:14 a.m. EDT on Thursday. The decline came after the company announced its first-quarter results following the market close on Wednesday.

So what

Global Blood Therapeutics reported net sales of $39 million in the first quarter, all of which stemmed from sickle-cell disease drug Oxbryta. This result fell well below the average analyst estimate of $47.3 million. The large revenue miss sparked today's sell-off of the biotech stock.

Vial with blood sample on top of a document with "Sickle-cell disease" printed on it

Image source: Getty Images.

The company blamed the disappointing performance for Oxbryta on COVID-19. It said there were fewer interactions with healthcare providers and patients in the first quarter due to the increased number of cases of COVID-19 in the U.S. As a result, new prescriptions for Oxbryta weren't as high as anticipated.

However, the company thinks this is only a short-term problem. It expects that new prescription volume will increase and even top pre-COVID-19 levels in the future.

Now what

Global Blood Therapeutics said that it's on track to kick off two pivotal late-stage studies of another sickle-cell disease drug, inclacumab, by mid-2021. It also expects to soon submit for U.S. approval of an expansion of the label for Oxbryta to include treating kids ages 4 to 11 who have sickle-cell disease.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Global Blood Therapeutics, Inc. Stock Quote
Global Blood Therapeutics, Inc.
$67.05 (0.07%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.